Manufacturers: Samchundang Pharm
SCD-411 (SCD411) is Samchundang Pharm's biosimilar of Eylea (aflibercept 2 mg), an ophthalmic medicine used for age-related macular degeneration. Phase III clinical trials began in August 2020, aiming at US and Japanese approval. In December 2025, the FDA accepted the proposed aflibercept biosimilar aBLA submitted with partner Fresenius Kabi. After earlier settlements in the US and Canada, Samchundang Pharm reached a global settlement with Regeneron Pharmaceuticals and Bayer in August 2026, dismissing pending patent litigation in Europe, Japan, and South Korea and clearing the path for commercialization.
SCD-411 (SCD411) is Samchundang Pharm's biosimilar of Eylea (aflibercept 2 mg), an ophthalmic medicine used for age-related macular degeneration. Phase III clinical trials began in August 2020, aiming at US and Japanese approval. In December 2025, the FDA accepted the proposed aflibercept biosimilar aBLA submitted with partner Fresenius Kabi. After earlier settlements in the US and Canada, Samchundang Pharm reached a global settlement with Regeneron Pharmaceuticals and Bayer in August 2026, dismissing pending patent litigation in Europe, Japan, and South Korea and clearing the path for commercialization.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
